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 ABSTRACT  
Aims: Low-grade ovarian endometrioid carcinomas may be associated with high-grade 
components. Whether the latter are clonally-related to and originate from the low-grade 
endometrioid carcinoma remains unclear. Here we employed massively parallel sequencing 
to characterize the genomic landscape and clonal relatedness of an ovarian endometrioid 
carcinoma containing low- and high-grade components.   
Methods and Results: DNA samples extracted from each tumor component (low-grade 
endometrioid, high-grade anaplastic, high-grade squamous) and matched normal tissue were 
subjected to targeted massively parallel sequencing using the 410 gene Integrated Mutation 
Profiling of Actionable Cancer Targets (MSK-IMPACT) sequencing assay. Somatic single 
nucleotide variants, small insertions and deletions, and copy number alterations were detected 
by state-of-the-art bioinformatics algorithms, and validated with orthogonal methods. The 
endometrioid carcinoma and the associated high-grade components shared copy number 
alterations and four clonal mutations, including SMARCA4 mutations, which resulted in loss 
of BRG1 expression. Subclonal mutations and mutations restricted to single components were 
also identified, such as distinct TP53 mutations restricted to each histologic component.   
Conclusions: Histologically distinct components of ovarian endometrioid carcinomas may 
display intra-tumor genetic heterogeneity but be clonally related, harboring a complex clonal 
composition. In the present case, SMARCA4 mutations were likely early events, whereas 
TP53 somatic mutations were acquired later in evolution.     
Keywords: Ovarian endometrioid carcinoma, high-grade transformation, massively parallel 
sequencing, mucinous metaplasia, copy number analysis, immunohistochemistry.  
 INTRODUCTION  
Ovarian endometrioid carcinomas (OECs) constitute 10-15% of ovarian carcinomas1 and 
closely resemble their uterine counterparts, being mostly low-grade, with frequent squamous 
differentiation, and unusual morphologic patterns such as mucinous differentiation.2, 3 
Highgrade OECs are relatively uncommon,3 and their repertoire of somatic genetic alterations 
has yet to be fully characterized.4 Rarer is the coexistence of low-grade and high-grade areas 
within OECs.5  
Massively parallel sequencing has revealed the phenomenon of intra-tumor genetic 
heterogeneity in cancer,6 which may correlate with histologic heterogeneity.7 Here we analyze 
a case of a low-grade OEC with mucinous differentiation and histologically distinct high-grade 
components to define their repertoire of somatic genetic alterations, their clonal relatedness, 
and whether the low-grade OEC constituted the substrate from which the highgrade 
components originated.  
MATERIALS AND METHODS  
Histopathologic, immunohistochemical and fluorescence in situ hybridization (FISH) 
analysis  
Upon approval from the local Institutional Review Board and written informed consent from 
the patient, the case was retrieved from the Department of Pathology, Rochester General 
Hospital and histologically characterized based on WHO criteria.1 The details of the 
immunohistochemical analysis (Supplementary Table S1) and ERBB2 (HER2) dual-color 
FISH8 are described in Supplementary Methods.   
 Targeted capture massively parallel and Sanger sequencing  
DNA samples extracted from histologically distinct tumor components, separately 
microdissected as previously described,7 and normal tissue were subjected to MSK-IMPACT 
(410 key cancer genes), as previously described.9, 10 Bioinformatic analyses for the 
identification of somatic mutations, their potential functional effect, copy number alterations 
(CNAs), cancer cell fractions (CCFs) and mutational signatures,9, 11-17 and for assessing clonal 
relatedness9 were performed as previously described (Supplementary Methods).9 Sequencing 
data were deposited into the NCBI Sequence Read Archive, under accession code 
SRP059543. Selected somatic mutations identified by MSK-IMPACT sequencing and 
restricted to one or two of the tumor components (n=64) were validated using high-depth 
targeted amplicon re-sequencing (Supplementary Table S2), and  
confirmed the accuracy of MSK-IMPACT results, with a validation rate of 98.7%.9, 11, 12, 18 
Sanger sequencing was employed to investigate the presence of hotspot somatic mutations 
of POLD1, as previously described18 (Supplementary Methods; Supplementary Table S3).   
RESULTS  
Case presentation  
A 68-year-old female presented with a left complex solid-cystic ovarian mass, measuring 
20.0x15.0 cm. Histologically the tumor was a grade 1 endometrioid carcinoma with mucinous 
differentiation and microscopically discrete foci of high-grade anaplastic carcinoma with 
rhabdoid/undifferentiated features, high-grade squamous cell carcinoma, and spindle cell 
sarcoma-like areas (Figure 1A). Tumor stage was pT1aN0. The patient did not receive 
adjuvant chemotherapy or radiotherapy, and is currently without evidence of disease 28 
months after diagnosis.  
 Repertoire of somatic genetic alterations  
Whilst the reactive sarcoma-like component lacked CNAs and likely constituted reactive 
stroma, the low-grade endometrioid carcinoma and high-grade anaplastic and squamous cell 
carcinomas displayed relatively simple genomes but shared focal similar CNAs (Figure 1B, 
Supplementary Figure S1, Supplementary Table S4), including 17p losses and 17q gains. 
Amplification of 17q, encompassing the ERBB2 locus, was identified in the endometrioid 
carcinoma, whereas the anaplastic carcinoma and squamous cell carcinoma harbored gains 
of 17q (Figure 1B, Supplementary Figure S1). FISH analysis validated these CNAs, but 
revealed heterogeneous ERBB2 amplification across components, characterized by an 
anatomically distinct amplified tumor population within the endometrioid carcinoma, and by 
admixed amplified and non-amplified cells in the anaplastic and squamous cell carcinomas 
(Figure 1C).   
MSK-IMPACT yielded a median depth of coverage of 425x (range 409x-536x; Supplementary 
Table S5) and, at variance with CNAs, revealed a high mutation burden. In total, we identified 
101 non-synonymous somatic mutations affecting 69 genes, 39 of which were pathogenic or 
potentially pathogenic mutations (Figure 2A, Supplementary Figure S2, Supplementary Table 
S6). No mutations were found in the sarcoma-like area, confirming its likely non-neoplastic 
nature.   
Given the high mutation load, we sought to define whether this case harbored genetic 
alterations consistent with a mutator phenotype.19 A clonal somatic missense POLE mutation 
(E349K) was identified by MSK-IMPACT in both high-grade carcinoma components, however 
it did not target a hotspot and was predicted to be non-pathogenic. POLD1 somatic hotspot 
mutations were not identified by Sanger sequencing (data not shown). All carcinomas retained 
MSH2, MSH6, MLH1 and PMS2 immunohistochemical expression, indicating DNA mismatch 
repair (MMR)-proficiency (Supplementary Figure S3). Furthermore, germline hereditary 
cancer gene testing (Myriad myRisk), including MMR genes, revealed no mutations (data not 
 shown). Given the lack of evidence of a hyper- or ultra-mutator phenotype, we investigated 
the mutational signatures that shaped the genomes of the histologically distinct components.20 
All samples harboring somatic mutations displayed the mutational signature 2 (Figure 2B), 
which has been linked to tumors with a high mutation burden and is associated with the 
APOBEC cytidine deaminase activity. No somatic mutations or CNAs affecting APOBEC 
family genes were detected in the samples analyzed.  
In agreement with the CNA analysis, the carcinoma components shared nine identical somatic 
mutations. Four of these shared mutations were clonal (i.e. estimated by  
ABSOLUTE21 to be present in virtually all cancer cells of the lesion analyzed) and truncal (i.e. 
present as clonal events in all neoplastic components analyzed). These likely early genetic 
events included missense mutations targeting NOTCH3 and MDC1, and concurrent nonsense 
and missense mutations affecting SMARCA4 (Y439* and K1390N, Figure 2A, Supplementary 
Figure S2, Supplementary Table S6), suggesting an early bi-allelic inactivation of SMARCA4. 
Indeed, immunohistochemistry revealed no expression of BRG1, the protein product of 
SMARCA4, in all carcinoma components (Figure 2C).   
Of 101 non-synonymous mutations, 9%, 12% and 52% were restricted to the squamous cell, 
anaplastic and endometrioid carcinoma components, respectively, some of which may 
contribute to the distinct phenotype of each specific component of this case (Figure 2A, 
Supplementary Figure S2, Supplementary Table S6). Nineteen mutations were shared solely 
by the high-grade squamous cell and anaplastic carcinomas, including likely-pathogenic 
mutations affecting CDKN2A, PTEN, PIK3R1 and APC. Consistent with these findings, PTEN 
expression was detected in the endometrioid carcinoma, whereas it was markedly reduced in 
the anaplastic and squamous cell carcinomas (Figure 2C). TP53 was inactivated in the 
endometrioid, anaplastic and squamous cell carcinomas by distinct clonal somatic mutations 
(E180K, Q331*, and E285K mutations, respectively), all coupled with LOH of the wild-type 
 allele (Figure 2A, Supplementary Table S6), providing evidence of convergent evolution.22 As 
expected,23 the two missense mutations present in the endometrioid and squamous cell 
carcinoma resulted in p53 overexpression, whereas the truncating mutation in the anaplastic 
carcinoma resulted in weak patchy p53 protein expression (Figure 2C).   
Clonal relatedness and decomposition  
A formal clonal relatedness analysis based on all somatic mutations demonstrated that the 
endometrioid, anaplastic and squamous cell carcinoma components were clonally related  
(p<0.05, Supplementary Figure S4). Given the clonal nature of the components, we next 
performed a clonal decomposition analysis (Figure 2D), which suggested that SMARCA4 
mutations were among the earliest genetic events. The endometrioid carcinoma evolved 
separately with the acquisition of clonal mutations affecting CDK12, MLH1 and MAPK1, 
whereas the anaplastic and squamous cell carcinomas stemmed from a common ancestor, 
sharing several clonal mutations, including those affecting CDKN2A, POLE and ERBB2. TP53 
mutations and ERBB2 amplification likely constituted later events in the tumor  
evolution.   
DISCUSSION  
Coexisting low-grade OEC and high-grade carcinoma components may be clonally related 
and display complex clonal architecture, with substantial intra-tumor heterogeneity. In the 
present case, bi-allelic inactivation of SMARCA4 associated with lack of BRG1 expression 
was a truncal genetic event, potentially driving its early development. Subclonal alterations, 
as well as mutations restricted to one or two components were identified. The presence of 
unique TP53 somatic mutations and subclonal heterogeneous ERBB2 amplification in the 
different components suggest clonal evolution and a convergent evolution22 in the progression 
to the histologically distinct carcinoma components.  
 SMARCA4 encodes for BRG1, a catalytic unit of the ATP-dependent switching and sucrose 
non-fermenting (SWI/SNF) chromatin regulators complex, frequently mutated in human 
malignancies.24, 25 Somatic and germline SMARCA4 mutations underpin a panoply of 
carcinomas, often displaying a rhabdoid phenotype,26 such as ovarian small cell carcinoma, 
hypercalcemic type.26-29 and the undifferentiated components of dedifferentiated endometrial 
carcinomas.30, 31 Our observation of bi-allelic inactivation of SMARCA4 in this case illustrates 
that loss of function of this gene is not necessarily restricted to tumors with a rhabdoid 
phenotype.   
The marked morphologic heterogeneity and high mutational burden of the case presented 
herein are reminiscent of those observed in POLE ultra-mutated or MMR-deficient 
hypermutated endometrial carcinomas.32, 33 This case, however, harbored neither DNA 
mismatch repair alterations nor POLD or POLE hotspot mutations. Rather, an enrichment for 
mutations consistent with the action of APOBEC cytidine deaminases was detected. 
Importantly, however, loss of SMARCA4 function has been linked to genetic instability and 
high mutational burden,34 and may provide another basis for the high mutational load and 
genetic and morphologic intra-tumor heterogeneity observed in the present case.  
In conclusion, our study revealed that intra-tumor histologic heterogeneity in an OEC may be 
underpinned by, or at least coincidental with, genetic heterogeneity. The unusual high-grade 
histologic components were however clonally related to the low-grade OEC, and the genetic 
alterations detected are consistent with convergent evolution in the progression of this tumor. 
Finally, our findings warrant further investigation of the role of chromatin remodeling genes in 
the development of genetically unstable low-grade OEC undergoing progression to high-grade 
carcinomas.   
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 FIGURE LEGENDS  
Figure 1: Histological features, repertoire of copy number alterations, and dual-color 
ERBB2 FISH analysis in an ovarian endometrioid carcinoma with mucinous 
differentiation and associated high-grade anaplastic carcinoma, squamous cell 
carcinoma and sarcoma-like components.   
(A) Representative micrographs (H&E; original magnification - 20x) of low-grade endometrioid 
carcinoma with mucinous differentiation, high-grade anaplastic carcinoma, high-grade 
squamous cell carcinoma and reactive sarcoma-like components. (B) Copy number 
alterations detected in the histologically distinct components of the tumor. Chromosomes are 
represented on the y-axis, with gains (light blue), losses (salmon), amplifications (dark blue) 
and homozygous deletions (dark red) plotted according to their respective genomic locations. 
(C) FISH analysis for ERBB2 in the histologically distinct components using dual-color probes 
for ERBB2 (red) and reference chromosome 17 (green). Note that the endometrioid carcinoma 
component, albeit considered to be ERBB2 amplified according to the ASCO/CAP 
guidelines,35 displayed a heterogeneous distribution of ERBB2 gene amplification 
(anatomically distinct amplified population, mean ERBB2 absolute number 5.5, ratio 
ERBB2/CEN17 2.6; non-amplified population, mean ERBB2 absolute number 1.6, ratio 
ERBB2/CEN17 1.6), whereas the anaplastic (mean ERBB2 absolute number 5.7, ratio 
ERBB2/CEN17 1.5) and squamous cell carcinoma (mean ERBB2 absolute number 4.6, ratio 
ERBB2/CEN17 1.8) components harbored ERBB2-amplified neoplastic cells (48% and 26% 
of cells with ≥6 ERBB2 copies, respectively) intermingled with neoplastic cells lacking ERBB2 
gene amplification. The reactive sarcoma-like components displayed diploid ERBB2 status 
(mean ERBB2 absolute number 1.7, ratio ERBB2/CEN17 1.1). FISH, fluorescence in situ 
hybridization.  
 Figure 2: Repertoire of non-synonymous somatic mutations, mutational signatures and 
clonal decomposition of the ovarian endometrioid carcinoma with mucinous 
differentiation, anaplastic carcinoma and squamous cell carcinoma components.   
(A) Heatmap depicting the cancer cell fraction of the somatic SNVs identified in each 
component. Each column represents one sample; mutations are reported in rows. The cancer 
cell fraction and clonality of the mutations were defined using ABSOLUTE.21 Note that no 
somatic mutations were detected in the sarcoma-like component. (B) The barplots illustrating 
the mutational signatures of all somatic SNVs of a given histologic component according to 
the 96 substitution classification defined by the substitution classes (i.e. C>A,  
C>G, C>T, T>A, T>C and T>G bins), and the 5’ and 3’ sequence context. The height of colored 
bars represents the normalized fraction of mutations attributed to each of the 96 subbins. The 
pie charts show the mutational signatures present in a given component, the sizes of the pie 
slices are proportional to the normalized fraction of the mutation types (i.e. C>A, C>G, C>T, 
T>A, T>C and T>G).9 (C) Representative micrographs of BRG1, p53 and PTEN expression in 
the endometrioid carcinoma, anaplastic carcinoma component and squamous cell carcinoma 
component (10x magnification). Loss of BRG1 protein expression is seen in the three 
components (lymphocytes and stromal cells serve as internal positive control); the p53 protein 
expression pattern differs between tumor components, consistent with their distinct private 
TP53 mutations; PTEN expression is retained in the endometrioid carcinoma areas, while the 
anaplastic carcinoma and squamous cell carcinoma components display marked reduction of 
PTEN expression. (D) Phylogenetic tree depicting the clonal evolution of the different 
histologic components. The length of the branches is proportional to the number of mutations 
that distinguish a given clone from its ancestral clone, and selected somatic mutations that 
define a given clone are shown. AC, anaplastic carcinoma component; CCF, cancer cell 
fraction; OEC, ovarian endometrioid carcinoma; SCC, squamous cell carcinoma component.   
  
 SUPPLEMENTARY FIGURE LEGENDS   
Supplementary Figure S1: Genome plots of the low-grade endometrioid carcinoma with 
mucinous differentiation, and the anaplastic carcinoma, squamous cell carcinoma and 
sarcoma-like components.   
In the genome plots the Log2 ratios, depicted on the y-axis, are plotted according to their 
genomic positions, shown in the x-axis. The chromosomes are delimited by alternating blue 
and gray bands.  
Supplementary Figure S2: Repertoire of somatic mutations of the endometrioid 
carcinoma with mucinous differentiation, and the anaplastic carcinoma and squamous 
cell carcinoma components.  
Heatmap depicting the SNVs indicated in each component. Each row represents one sample; 
mutations are reported in columns. Mutation types are color-coded according to the legend. 
Please note that the results of the sarcoma-like component are not included in this figure, 
given that no somatic mutations were detected. AC, anaplastic carcinoma component; OEC, 
endometrioid carcinoma; SCC, squamous cell carcinoma component; SNV, single nucleotide 
variant.  
Supplementary Figure S3: Immunohistochemical analysis of DNA mismatch repair 
proteins.  
Representative micrographs of immunohistochemical analysis of (A) MSH2, (B) MSH6, (C) 
MLH1, (D) PMS2 expression in the endometrioid carcinoma (10x magnification).  
  
 Supplementary Figure S4: Clonal relatedness analysis of the endometrioid carcinoma 
with mucinous differentiation, and the anaplastic carcinoma and squamous cell 
carcinoma components.   
Clonality index of the different histologic components of the case, defined as the likelihood of 
the different histologic components sharing mutations not expected to have co-occurred by 
chance. The cut-off for defining two samples as being clonally related not by chance on the 
basis of the somatic mutations identified is highlighted by the red dashed line. This analysis 
revealed that the anaplastic carcinoma and the squamous cell carcinoma components were 
clonally related, and both were clonally related to the endometrioid carcinoma. AC, anaplastic 
carcinoma component; OEC, endometrioid carcinoma; SCC, squamous cell carcinoma 
component.  
   
   
  
  
  
    
  
